Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352030 | 0.79 | FGFR1 (0.35) | DGAT1MAPT | |
| SCHEMBL29854726 | 0.79 | FGFR1 (0.35) | DGAT1MAPT | |
| SCHEMBL30544510 | 0.78 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL1291499 | 0.77 | HDAC1 (0.38) | DGAT1MAPT | |
| SCHEMBL13737043 | 0.77 | DGAT1 (0.34) | DGAT1MAPT | |
| SCHEMBL29514152 | 0.76 | DGAT1 (0.40) | DGAT1MAPT | |
| SCHEMBL101528 | 0.76 | DGAT1 (0.40) | DGAT1MAPT | |
| SCHEMBL31497497 | 0.75 | DGAT1 (0.37) | DGAT1MAPT | |
| SCHEMBL13906311 | 0.75 | DGAT1 (0.34) | DGAT1MAPT | |
| SCHEMBL31410899 | 0.75 | DGAT1 (0.34) | DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022033430-A1 | HETEROTRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳微芯生物科技股份有限公司 | 2022-02-17 | — | — | WO | disclosed |
| US-20120330012-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120330012-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2012149280-A2 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330012-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | DGAT1 2907/4885MAPT 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.